Will someone be able to write my complex nursing care plan for me?
JCJC Complex Nursing
|
GENERAL PATIENT INFORMATION |
HEALTH HISTORY |
|
||
|
Age: 84 Race: Caucasian Sex: Male MS: Divorced |
Chronic or Previous Health Problems (include date of onset if known): -Arthritis -COPD -Lung dz -Hypercholesterolemia -HTN -Cancer -Multiple myeloma -Muscle Cramps -Thyroid
___________________________________________________ History of current symptoms: Denied any other pain or complications besides his arm |
Diet: Healthy Heart, |
||
|
Height: 172.72 cm |
Weight: 86.18kg |
Code Status: Full Resuscitation |
|
Activity Ordered: Activity as tolerated |
|
Religion: No preference |
Economic Status: Medicare |
|
Activity Possible: Bed rest. Activity as tolerated |
|
|
Perception of Health/Reason for Admission (pt’s own words): |
|
Nutrition: □ PEG Tube PO |
||
|
“I broke my arm” |
|
|
||
|
|
|
Elimination: □ Foley □ Ostomy—Type: Void I & O schedule: |
||
|
Admitting Medical Diagnosis: Syncope, Hypotension, ARI |
|
|
||
|
|
|
Wounds/ Wound Care: No wound care |
||
|
|
Previous Surgeries (include date): -Left heart cardiac 8/11/15 -Coronary arteriography using two caths 8/11/15 -Biopsy of bone marrow 4/16/15 -Eye -Hernia -HIp replacement, -Knee -Shoulder replacement -Thyroid |
|
||
|
|
|
Respiratory: No supplemental O2 □ O2 @ ______ L/min via _________________________ □ Incentive Spirometer every ___________ □ Respiratory Treatments: -Documented: Albuterol (Albuterol 90 mcg/inh inhalation) - 2 puffs, INH, BID, PRN SOB or wheezing -Documented: Fluticasone-salmeterol - 1 puff, INH, BID # 60 EA -Fluticasone-salmeterol (Advair Diskus 250 mcg-50 mg inhalation powder) - 1 puff, Inh-oral disk, INH, BID, Routine • Ventilator Settings_________________________ |
||
|
Date of Admission: 2/12/17 |
|
|
||
|
Surgical Procedures: No surgeries since admission Date: |
|
|
||
|
|
Home Medications: -Aspirin (Aspirin EC 81 mg) = 1 tab(s), oral daily -Prochlorperazine (Compazine) = 1 tab, oral q 6hr -Multivitamin with mineralys (PreserVision oral capsule) = 1 cap, oral, BID, presersivion with Lutein -Fluticasone - Salmeterol - 1 puff, INH, BID, #60 EA -Calcium-Vitamin D (Calcium 500 + D oral tablet, chewable) - 1 tab chewed BID -Multivitamin - 1 tab, oral, daily -Acetaminophen-hydrocodone (Norco 5mg/325mg) - 1 tab, oral, q4hr, PRN for pain -Omega-3 polyunsaturated fatty acids (omega - 3 polyunsaturated fatty acids 1000 mg oral capsule) - 1,000 mg = 1 cap, oral, once a day (bedtime) #60 cap -Potassium chloride - 10 mEq, oral daily -Memantine (Namenda) - 10mg = 1 tab, oral, BID #60 tabs -Cetirizine (Cetirizine 10 mg oral tab) = 10 mg = 1 tab, oral daily #30 tabs -Cyanocobalamin (Vita B12 100 mcg oral tablet) - 100 mcg = 1 tab, oral, daily #30 tab -Levothyroxine (levothyroxine 112 mcg (0.112 mcg) oral tablet) - 112 mcg = 1 tab, oral daily # tab -Polyethylene glycol 3350 (MiraLax) - 17 gm 1 packet, oral, daily -Ropinirole (Ropinirole 2 mg oral tablet) - 2 mg = 1 tablet, oral, once a day #270 tab -Albuterol (Albuterol 90 mcg/inh inhalation) - 2 puffs, INH, BID, PRN SOB or wheezing -Omeprazole (Prilosec 20 mg oral delayed releases capsule) - 20 mg = 1 cap, oral, daily -Isosorbide mononitrate - 30 mg, oral, qAM, 0 refill -Allupurinol (allupurinol 300 mg oral tab) - 300 mg = 1 tab, oral, daily #30 days -Ferrous sulfate (ferrous sulfate 325 mg (65 mg elemental iron) oral tab) - 1 tab, once a day #270 tabs -Lisinopril (Lisinopril 10 mg oral tab) - 40 mg, oral daily #30tabs -Cholecalciferol (Vitamin D3 400 intl units oral tabs)- 400 int unit = 1 tab(s), oral, daily -Carbamide peroxide otic (Debrox 6.5% otic soln)-5 drops, otic, BID, # 15 mL -Donepezil (Donepezil 5 mg oral tab) 5mg = 1 tab, oral once a day at bedtime #30 tabs -Ondansetron (Zofran 8 g oral tab) - 8 mg = 1 tab, oral, q6hr, PRN N/V #9 tabs -Amlodipine (Amlodipine 10 mg oral tab) - oral daily |
□ Accuchecks: □ ac & hs □ sliding scale insulin: No accuchecks/sliding scale
|
||
|
Allergies (include symptoms): Bactrim and Codeine |
|
|
||
|
|
|
IV: (includes site change date) LAC site due to be changed 02/16/17 |
||
|
|
|
Multidisciplinary: Physician, Nurse, RT |
||
|
Patient Classification: Class II. INtermediate care, moderately ill, both pt and nurse participate in care
|
|
|
||
|
Priority Dx #1: R/f injury r/t altered LOC secondary to inadequate cerebral blood flow; increased peripheral resistance; increased concentration of lipids in the blood |
Priority Dx #2: Ineffective airway clearance r/t increased production of tenacious secretions and retained secretions |
Priority Dx #3: Chronic pain r/t to destruction of tissues/bone; degeneration of joint |
||
|
VS q4 hours |
Assess for s/s of ineffective airway clearance (ex: abnormal breath sounds; rapid, shallow respirations; dyspnea; cough)
|
Assess VS q 4 hours (including pain on a 0-10 scale)
|
||
|
Monitor BP and pulse |
Improve airway patency (encourage hydration 2 to 3 L/day) |
If pain present, administer acetaminophen-hydrocodone (Norco 5mg/325 mg) - 1 tab,oral, q4hr, PRN for pain |
||
|
Check O2 Sat |
Promote bed rest (the pt should assume a comfortable position to promote rest and breathing ex: Semi-Fowler’s position position) |
Instruct pt to frequently change positions |
||
|
Check capillary refill |
Turn pt q 2 hours as ordered to enhance secretion clearance and pulmonary ventilation and perfusion |
Encourage the use of relaxation techniques including breathing control and guided imagery |
||
|
Keep bed in low position with side rails up when pt is in bed |
Instruct and assist pt to deep breathe and cough or “Huff” every 1-2 hours |
Give ice-cold compress if needed to relieve the pain and swelling during the acute period of arthritis |
||
|
Keep needed items within reach |
Administer albuterol (albuterol 90 mcg/inh inhalation aerosol) - 180 mcg = 2 puffs, inH -oral, INH, BID, PRN for SOB or wheezing |
|
||
|
Encourage pt to ask for assistance whenever needed |
Administer fluticasone-salmeterol (Advair Diskus 250 mcg-50 mg, inhalation powder) - 1 puff, inh-oral disk, INH, BID, Routine |
|
||
|
Instruct and assist pt to rise and change positions slowly |
|
|
||
|
Instruct pt to wear nonskid socks |
|
|
STUDENT: _________________________________ UNIT/ROOM #: ______ DATES OF CARE: ___________________ __________ Front sheet/Orders=15 points
|
Diagnosis
|
Diagnosis
|
Diagnosis
|
|
Interventions
|
Interventions
|
Interventions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnosis
|
Diagnosis
|
Diagnosis
|
|
Interventions
|
Interventions
|
Interventions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnosis
|
Diagnosis
|
Diagnosis
|
|
Interventions
|
Interventions
|
Interventions
|
|
|
|
|
|
|
|
|
|
|
|
|
Current Orders:
STUDENT: ____________________________________ DATES OF CARE: ________ Med sheets/Labs=15 points________
(Must provide references for each)
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Influenza virus Vaccine (Flu Vaccine) |
Immunization |
0.5 mL, syringe |
IM |
As directed |
At risk for infections |
could have allergic rxn if allergic to egg protein |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: and during administration. Assess previous immunization hx and hx of hypersensitivity |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Fluticasone-Salmeterol (Advair Diskus powder pgs 1105, 347 |
Corticosteroid - Bronchodilator |
250 mcg - 50 mg |
Oral, inhalation |
1 puff, BID |
Hx of COPD and lung dz and has ARI. Bronchodilates |
SE: headache AE: asthma-related death |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Assess lung sounds, pulse and BP before administering. Drug interactions: MAO inhibitors and tricyclic antidepressants, CYP3A4 |
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Acetaminophen-hydrocodone (Norco 5 mg / 325 mg) Davis Drug Guide pg 651 |
Opiod agonists/nonopioid analgesic combinations |
5mg/325 mg |
oral |
q4hr, PRN for pain |
Therapeutic: decreases in severity of moderate pain. Suppression of the cough reflex |
SE: confusion, dizziness, sedation, hypotension, constipation, dyspepsia, nausea |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: MAO inhibitors, CYP3A4 inhibitors, alcohol, antihistamines, sedative/hypnotics, kava-kava, valerian, skullcap, chamomile Implications: Assess BP, pulse and respirations before and periodically during administration |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Acetaminophen Davis Drug Guide pg 97 |
Antipyretics, nonopioid analgesics |
1,000 mg |
oral |
2 tabs |
Antipyretics, analgesia |
AE: hepatotoxicity; acute generalized exanthema |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: warfarin, alcohol, isoniazid, rifampin, rifabutin, phenytoin, barbiturates and carbamazepine Implications: assess overall health status and alcohol usage before administering acetaminophen. Assess type and location of pain |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Memantine (Namenda) Davis Drug Guid pg 800-801 |
Anti-alzheimer’s agent |
10 mg |
oral |
BID |
Displaying cognitive decline. Decreased symptoms of dementia/cognitive decline. |
Dizziness, fatigue, h/a, sedation, HTN, rash, diarrhea, wt gain, urinary frequency, anemia |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: carbonic anhydrase inhibitors, sodium bicarbonate Implications: Assess cognitive function (memory, attention, reasoning, language, ability to perform simple tasks) |
||||||
|
|
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Cetrizine (Zyrtec) Davis Drug Guide pg 300 - 301 |
Allergy, cold and cough remedies, antihistamines |
10 mg |
oral |
daily |
ARI. Decreased symptoms of histamine excess (sneezing, rhinorrhea, ocular tearing and redness, pruiritus) |
CNS: dizziness, drowsiness |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: alcohol, opioid analgesics, sedative/hypnotics Implications: Assess allergy sx, assess lung sounds and character of bronchial secretions |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Methylprednisolone (Medrol) 353 |
Intermediate-acting corticosteroids |
100 mg = 1.6 mL |
injection, IV |
As directed |
suppression of inflammation and modication of the normal immune response |
SE: depression, euphoria, hypertension, anorexia, nausea, acnes, decrease wound healing, ecchymoses, fragility, hirsutism, petechiae, adrenal suppression, muscle wasting, osteoporosis, cushingoid appearnace AE: peptic ulceration, thromboembolism |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interaction: thiazide and loop diuretics or amphotericin B, digoxin, PHenytoin, phenobarbital and rifampin, NSAID, fluoroquinolones, Antacids, ketoconazole, itraconazole Implications: Assess for adrenal insufficiency |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Diphendramine Davis Drug Guide pg 431 |
Allergy, Cold and cough remedies, antihistamines, antitussive |
12.5 mg = 0.75 mL, |
IV injection |
1 dose as directed |
ARI. Decreased symptoms of histamine excess (sneezing, rhinorrhea, nasal and ocular pruirtus, ocular tearing and redness, urticaria). Suppression of cough |
SE: drowsiness, anorexia, dry mouth |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: antihistamines, alcohol, opioid analgesics, sedative/hypnotics, tricyclic antidepressants, quinidine, MAO inhibitor Implication: Assess frequency and nature of cough, lung sounds, and amount and type of sputum produced |
||||||
|
|
||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Levothyroxine (Synthroid) Davis Drug Guide pg 757 |
Thyoid |
125 mcg |
oral |
daily |
Thyroid supplementation in hypothyroidism. Therapeutic: replacement in hypothyroidism to restore normal hormonal balance |
Can cause angina pectoris, arrhythmias, tachycardia, abdominal cramps |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: warfarin, insulin, oral hypoglycemic agents, estrogen Implications: assess apical pulse and BP prior to and periodically during therapy. ASsess for tachyarrhythmias and chest pain |
||||||
|
|
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
|
Albuterol pg 116 Davis Drug Guide |
Bronchodilator |
180 mcg = 2 puffs |
oral inhalation |
Inh, BID, PRN for SOB or wheezing |
ARI. Hx of COPD. Bronchodilation |
SE: nervousness, restlessness, tremor, chest pain, palpitations AE: Paradoxical bronchospasm |
|
|
|
|
|
|
|
|
|
Nursing Implications and Interactions: Drug interactions: adrenergic agents, MAO inhibitors, Beta blockers, digoxin, tricyclic antidepressants, potassium-losing diuretics Implications: Observe for paradoxical bronchospasm (wheezing) |
||||||
|
|
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Ropinirole (Requip) Davis Drug Guide pg 1099 |
Dompamine agonists |
2 mg |
oral |
once a day |
Decreased tremore and rigidity in Parkinson’s dz. Decreased leg restlessness. |
SE: dizziness, syncope AE: sleep attacks |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nursing Implications and Interactions: drug interactions: p450 CYP1A2,, estrogen, phenothiazines, butyrophenones, thioxanthenes or metoclopramide Implications: Assess pt for drowsiness and sleep attacks. ASsess pt for concomittant medications that have sedating effects or may increase serum ropinirole levels |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Bortezomib (Velcade) Davis Drug Guide pg 229 |
Proteasome inhibitors |
2.2 mg = 0.88 mL |
Subq |
|
Death of rapidly replicating cells, particulary malignant ones |
SE: fatigue, malaise, weakness, hypotension, anorexia, constipation, diarrhea, nausea, vomiting, anemia, neutropenia, thrombocytopenia, peripheral neuropathy, fever AE: progressive multifocal leukoencephalopahty, reversible posterior leukoencephalopathy syndrome, liver failure, bleeding |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nursing Implications and Interactions: Drug interactions: antivirals, amiodarone, nitrofuratoin, isoniazid Implications: Monitor for s/s of RPLS (h/a , seizure, lethargy, confusion, blindness). HTN. Assess for any new s/s that may be suggestive of PML |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Famotidine (Pepcid) Davis Drug Guide 637 |
Anti-ulcer agent |
20 mg = 50 mL |
IV soln |
200 mL/hr, infuse over 15 min |
Pt on bedrest. Healing and prevention of ulcers. DEcreased sx of gastroesophageal reflux. Decreased secretion of gastric acid. |
SE: confusion AE: arrhythmias, agranulocytosis, aplastic anemia |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nursing Implications and Interactions: Drug interactions: Benzodiazepines, chlordiazepoxide, diazepam, beta blockers, caffeine, CCB, carbamazepine, cyclosporine, dofetilide, lidocaine, metronidazole, mexiletine, nefazodone Implications: Assess for epigastric or abdominal pain and frank or occult blood in teh stool, emesis or gastric aspirate. Monitor CBC with differential periodically during therapy |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Medication generic/trade |
Classification/ mechanism of action |
Dose |
Route |
Frequency |
Why the patient is taking this medication |
Side Effects |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Enoxaparin (Lovenox) Davis Drug Guide pg 634 |
Anticoagulants Antithrombotics |
30 mg = 0.3 mL |
Sub q injection |
daily |
Prevention of clots |
Common SE: anemia AE: bleeding |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nursing Implications and Interactions: Drug interactions: warfarin, aspirin, NSAIDs, dpyridamole, clopidogrel, ticlopidine, eptifibatide, tirofiban and thrombolytics |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
|
|
|
|
Lab Studies |
Date |
Normal Values |
Patient Values |
Reason for Abnormal in YOUR patient (with reference) |
|
__ CBC WNL X |
|
|
|
|
|
RBC RBC |
2/12/17 2/13/17 |
4.7-6.1 4.7-6.1 |
(L) 3.62 (L) 3.13 |
Multiple Myeloma. Pagana pg 442 Multiple Myeloma. Pagana pg 442 |
|
Hgb Hgb |
2/12/17 2/13/17 |
14-18 14-18 |
(L) 11.9 (L) 10.1 |
Multiple Myeloma. Pagana pg 284 Multiple Myeloma. Pagana pg 284 |
|
Hct Hct |
2/12/17 2/13/17 |
42-52% 42-52% |
(L) 35.9 (L) 30.6 |
Multiple Myeloma. Pagana pg 280 Multiple Myeloma. Pagana pg 280 |
|
MCH MCH |
2/12/17 2/13/17 |
27-31 27-31 |
(H) 33 (H) 32 |
Elevated lipid levels. Pagana pg 445 Elevated lipid levels. Pagana pg 445 |
|
RDW RDW |
2/12/17 2/13/17 |
11-14.5% 11-14.5 |
(H) 16.0 (H) 16.0 |
Elevated lipid levels. Pagana pg 445 Elevated lipid levels. Pagana pg 445 |
|
MPV MPV |
2/12/17 2/13/17 |
7.4-10.4 7.4-10.4 |
(L) 6.8 (L) 6.8 |
Cancer chemo substance. Pagana pg 408 Cancer chemo substance. Pagana pg 408 |
|
Mono Abs |
2/12/17 |
100-700 |
(H) 0.60 |
Drug therapy.: prednisone. Pagana 532 |
|
Lymph Auto |
2/13/17 |
20-40 |
(L) 20.1 |
Drug therapy. Pagana pg 530-532 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cardiac testing WNL except |
|
|
|
|
|
Total CK Total CK Total CK CK MB CK MB CK MB |
2/12/17 2/13/17 2/13/17 2/12/17 2/13/17 2/13/17 |
55-170 55-170 55-170 0% 0% 0% |
Normal 77 Normal 59 Normal 67 Normal 3.50 Normal 2.60 Normal 2.90 |
Normal Normal Normal Normal Normal Normal |
|
Troponin Troponin Troponin Myoglobin Myoglobin Myoglobin |
2/12/17 2/13/17 2/13/17 2/12/17 2/13/17 2/13/17 |
< 0.1- 0.03ng/mL <0.1 - 0.03 ng/mL < 0.1 - 0.03 ng/mL < 90% < 90% < 90% |
(L) < 0.02 (L) < 0.02 (L) < 0.02 Normal 102 Normal 64 Normal 56 |
According to Pagana, normal According to Pagana, normal According to Pagana, normal Normal Normal Normal |
|
ABG’s WNL except |
|
|
|
|
|
No ABG’s |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Coagulation study: No coagulation study |
|
|
|
|
|
|
|
|
|
|
|
Blood C/S: |
|
|
Negative |
|
|
U/A |
2/12/17 |
|
|
|
|
Color Spec gravity UA BI Rlt Urobilogen Blood Glu Ketones Protein Nitrate Leuk Est |
|
|
Yellow < = 1.005 Neg 6.0 0.2 Eu/dL Neg Neg Ketones Neg Neg Neg |
|
|
Lab Studies |
Date |
Normal Values |
Patient Values |
Reason for Abnormal in YOUR patient (with reference) |
|
Chemistry WNL except |
|
|
|
|
|
Sodium |
2/12/17 |
136 - 145 |
(L) 133.0 |
Pagana pg 466 - 467 Deficient dietary intake |
|
BUN BUN |
2/12/17 2/13/17 |
10-20 10-20 |
(H) 37 (H) 30 |
Pagana pg 511 dehydration Pagana pg 511 Dehydration |
|
Creatinine Creatinine |
2/12/117 2/13/17 |
0.5-1.2 0.5-1.2 |
(H) 1.86 (H) 1.73 |
Pagana pg 191 Dehydration Pagana pg 191 Dehydration |
|
GFR African American GFR African American |
2/12/17 2/13/17 |
87-107 87-107 |
(L) 42 (L) 46 |
Pagana pg 193 Dehydration Pagana pg 193 Dehydration |
|
GFR Non African American GFR Non African American |
2/12/17
2/13/17 |
87-107
87-107 |
(L) 35
(L) 38 |
Pagana pg 193 Dehydration
Pagana pg 193 Dehydration |
|
Calcium |
2/13/17 |
9.0 - 10.5 |
(L) 7.9 |
Pagana 138 Drug therapy (Albuterol) |
|
Glucose Level |
2/12/17 |
70-100 |
(H) 124 |
Pagana pg 256 Corticosteroids |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diagnostic Testing, EKG’s, etc. |
Date |
Interpretation |
|
XR Chest 1 View Portable |
2/12/17 |
Stable exam; no acute process |
|
CT Head |
2/12/17 |
1) Cerebral atrophy & evidence of mild chronic microvascular ischemia, which appear to be stable 2) NO acute intracranial abnormality 3) Small amount of fluid inferior in the L mastoid air cells, which may be related to mastoid effusion clinical correlation is necessary to include mastoiditis |
|
U/S Carotid Duplex Comp Bil |
2/13/16 |
NO significant stenosis identified |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STUDENT: _________________________________________________ DATES OF CARE: __________________________________
Daily focused assessment of systems using AD Nursing assessment guides . __________ 20 points
CARDIOVASCULAR |
ENDOCRINE |
|
|
|
|
|
|
|
GENITOURINARY |
|
|
|
|
|
MUSCULOSKELETAL |
|
|
|
|
|
|
|
|
RESPIRATORY |
|
|
|
|
|
INTEGUMENTARY |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPRODUCTIVE |
Patient’s General Appearance |
Growth and Development |
|
|
|
Patient’s Age: _______ |
|
|
|
|
|
GASTROINTESTINAL |
Usual Sleep Pattern |
|
|
|
|
|
|
|
|
Assessment of How Each Developmental Task is Met or Unmet and Summary of resolution
|
SENSORINEURAL |
|
|
|
|
Activities to Promote Health |
|
|
|
_____________________________________ Activities needed to improve health
|
|
|
NURSING DIAGNOSIS, GOALS AND OUTCOME CRITERIA 5 points
Diagnosis: R/f injury r/t altered LOC secondary to inadequate cerebral blood flow; increased peripheral resistance; increased concentration of lipids in the blood
Goal: TPW not become injured AEB no new bruises, broken bones or bleeding
Outcome:
|
NURSING INTERVENTIONS Individualized and Applicable in order of priority 10 points
|
PATHOPHYSIOLOGY to support Nursing Diagnosis and Intervention (must paraphrase and reference) 15 points
|
EVALUATION OF INTERVENTIONS AND ACHIEVEMENT OF GOALS 10 points
|
|
NURSING DIAGNOSIS, GOALS AND OUTCOME CRITERIA 5 points
Ineffective airway clearance r/t increased production of tenacious secretions and retained secretions
|
NURSING INTERVENTIONS Individualized and Applicable in order of priority 10 points
|
PATHOPHYSIOLOGY to support Nursing Diagnosis and Intervention (must paraphrase and reference) 15 points
|
EVALUATION OF INTERVENTIONS AND ACHIEVEMENT OF GOALS 10 points
|
|
NURSING DIAGNOSIS, GOALS AND OUTCOME CRITERIA 5 points
Chronic pain r/t to destruction of tissues/bone; degeneration of joint
|
NURSING INTERVENTIONS Individualized and Applicable in order of priority 10 points
|
PATHOPHYSIOLOGY to support Nursing Diagnosis and Intervention (must paraphrase and reference) 15 points
|
EVALUATION OF INTERVENTIONS AND ACHIEVEMENT OF GOALS 10 points
|
STUDENT: ________ DATES OF CARE: _______
INTERPERSONAL INTERACTION ________10 points
1. Describe the time spent with your patient/family. Describe the predominant mood of your patient/family (support your findings with facial expressions, motor behavior and an example of words used to illustrate the mood). Also identify underlying themes that preoccupied the patient’s/family’s thoughts noted during the interaction.
2. Describe and give examples of the communication patterns of the patient with significant others and other health team members. (Spontaneous, logical, relaxed, forced, pressured, tangential or circumstantial?) Did you assess any abnormalities such as loose associations, neologisms?
3. Identify your patient’s/family’s significant stressors. Describe how you assessed and responded verbally and non-verbally to stressors and concerns. How did the patient/family react to your attempts to communicate? How did they respond to the primary nurse assigned? Was there a difference? What do you suppose were some of the reasons for the different responses?
4. Identify the barriers and personal biases that affected or could have affected your nurse- patient relationship.
5. What could you have said or done differently to enhance therapeutic communication and promote a better nurse patient relationship with this patient/family?